Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Constellation Pharmaceuticals	Kiniksa Pharmaceuticals	Pliant Therapeutics	Arcturus Therapeutics	Zogenix
Symbol	NASDAQ:CNST	NASDAQ:KNSA	NASDAQ:PLRX	NASDAQ:ARCT	NASDAQ:ZGNX
Price Information
Current Price	$20.50	$15.30	$32.87	$27.23	$18.74
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.2	1.7	2.0	1.6	1.7
Analysis Score	3.4	3.5	3.5	3.1	3.4
Community Score	2.4	2.4	4.6	2.6	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	2.5	1.7	1.7	1.7
Earnings & Valuation Score	0.0	0.0	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$40.33	$37.00	$49.20	$69.58	$59.00
% Upside from Price Target	96.75% upside	141.83% upside	49.68% upside	155.54% upside	214.83% upside
Trade Information
Market Cap	$982.24 million	$1.04 billion	$1.18 billion	$716.69 million	$1.05 billion
Beta	2.8	0.03	N/A	3.01	1.6
Average Volume	461,965	476,570	154,664	1,085,341	803,684
Sales & Book Value
Annual Revenue	N/A	N/A	$57.05 million	$20.79 million	$3.65 million
Price / Sales	N/A	N/A	20.67	34.47	286.56
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$8.23 per share	$4.10 per share	N/A	$1.70 per share	$5.54 per share
Price / Book	N/A	N/A	∞	16.02	3.38
Profitability
Net Income	$-85,550,000.00	$-161,870,000.00	$-630,000.00	$-25,990,000.00	$-419,500,000.00
EPS	($3.04)	($2.99)	N/A	($2.15)	($3.90)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	20.83%	-506.70%	-8,758.48%
Return on Equity (ROE)	-28.88%	-53.65%	16.55%	-52.32%	-53.91%
Return on Assets (ROA)	-24.98%	-49.11%	8.33%	-33.21%	-36.49%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.05%	N/A	N/A	0.06%	N/A
Current Ratio	15.81%	15.20%	27.91%	11.21%	4.58%
Quick Ratio	15.81%	15.20%	27.91%	11.21%	4.58%
Ownership Information
Institutional Ownership Percentage	N/A	42.00%	79.46%	74.33%	96.57%
Insider Ownership Percentage	10.60%	70.63%	N/A	12.60%	3.50%
Miscellaneous
Employees	154	168	78	118	218
Shares Outstanding	47.91 million	68.23 million	35.88 million	26.32 million	55.81 million
Next Earnings Date	8/4/2021 (Estimated)	7/29/2021 (Estimated)	8/10/2021 (Estimated)	8/9/2021 (Estimated)	8/4/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Zogenix to Participate in the BofA Securities 2021 Healthcare Conference - Yahoo Finance finance.yahoo.com - May 11 at 6:54 PM
	Zogenix to Participate in the BofA Securities 2021 Healthcare Conference finance.yahoo.com - May 11 at 6:54 PM
	Zogenix Launches Global Program to Boost Access to Fintepla - Dravet Syndrome News dravetsyndromenews.com - May 11 at 1:53 PM
	Zogenix: Q1 Earnings Snapshot - Miami Herald miamiherald.com - May 8 at 12:59 PM
	Zogenix (NASDAQ:ZGNX) Posts Earnings Results, Misses Expectations By $0.02 EPS americanbankingnews.com - May 7 at 4:32 PM
	Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results - Yahoo Finance finance.yahoo.com - May 7 at 3:18 PM
	Zogenix (NASDAQ:ZGNX) Trading 6.6% Higher americanbankingnews.com - May 7 at 12:44 PM
	Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Zogenix (ZGNX) and Dicerna Pharma (DRNA) - Smarter Analyst smarteranalyst.com - May 7 at 10:14 AM
	Does Zogenix, Inc. (ZGNX) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver investorsobserver.com - May 7 at 10:14 AM
	Zogenix: Q1 Earnings Snapshot - Westport News westport-news.com - May 7 at 10:14 AM
	Zogenix EPS beats by $0.02, beats on revenue - Seeking Alpha seekingalpha.com - May 7 at 12:26 AM
	Recap: Zogenix Q1 Earnings - Benzinga benzinga.com - May 7 at 12:26 AM
	Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results - GlobeNewswire globenewswire.com - May 6 at 7:26 PM
	Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results finance.yahoo.com - May 6 at 7:26 PM
	Is Zogenix, Inc. (ZGNX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver investorsobserver.com - May 6 at 2:25 PM
	Zogenix (NASDAQ:ZGNX) Hits New 12-Month Low at $16.89 americanbankingnews.com - May 6 at 12:44 PM
	Global Needle-Free Injection Device Market 2021 Potential Growth \| Zogenix, Antares Pharma, Akra Dermojet, Inovio, Eternity Healthcare – Jumbo News - Jumbo News jumbonews.co.uk - May 6 at 7:59 AM
	$12.48 Million in Sales Expected for Zogenix, Inc. (NASDAQ:ZGNX) This Quarter americanbankingnews.com - May 6 at 2:48 AM
	Zogenix Q1 2021 Earnings Preview - Seeking Alpha seekingalpha.com - May 5 at 9:57 PM
	Should You Buy Zogenix, Inc. (ZGNX) Stock After it Has Fallen 9.38% in a Week? - InvestorsObserver investorsobserver.com - May 5 at 11:55 AM
	Outlook on the Needle Free Diabetes Management Global Market to 2029 - Development of Next Generation Glucose Sensors Presents Opportunities - PRNewswire prnewswire.com - May 4 at 6:48 PM
	-$0.98 Earnings Per Share Expected for Zogenix, Inc. (NASDAQ:ZGNX) This Quarter americanbankingnews.com - May 4 at 12:26 PM
	Booming Growth in Long-Acting Injectables Market Analysis Report 2021 and Forecast to 2027 with different segments, Key players are Eli Lilly,Pfizer,GlaxoSmithKline,Johnson & Johnson,Lupin Limited,Zogenix - Good News Gum goodnewsgum.com - May 2 at 1:39 PM
	Needle Free Diabetes Management Market to Witness Growth Acceleration by Top Key Players – Zogenix, 3M, Antares Pharma Inc., Glide Pharmaceutical Technologies, Injex Pharma AG, Pharmajet - Good News Gum goodnewsgum.com - April 30 at 2:08 PM
	Analysts Estimate Zogenix (ZGNX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance finance.yahoo.com - April 29 at 6:31 PM
	Zogenix (NASDAQ:ZGNX) Stock Rating Upgraded by Zacks Investment Research marketbeat.com - April 23 at 5:59 AM
	Zogenix (NASDAQ:ZGNX) Upgraded at Zacks Investment Research marketbeat.com - April 16 at 6:30 AM

Date	Company	Brokerage	Action
4/7/2021	Constellation Pharmaceuticals	Royal Bank of Canada	Reiterated Rating
1/25/2021	Constellation Pharmaceuticals	BMO Capital Markets	Upgrade
9/24/2020	Constellation Pharmaceuticals	Oppenheimer	Reiterated Rating
9/3/2020	Constellation Pharmaceuticals	Brookline Capital Management	Initiated Coverage
8/9/2020	Constellation Pharmaceuticals	Jefferies Financial Group	Reiterated Rating
8/6/2020	Constellation Pharmaceuticals	HC Wainwright	Reiterated Rating
6/24/2020	Constellation Pharmaceuticals	JMP Securities	Initiated Coverage
3/11/2020	Constellation Pharmaceuticals	Robert W. Baird	Lower Price Target
3/11/2020	Constellation Pharmaceuticals	Cowen	Reiterated Rating
2/13/2020	Constellation Pharmaceuticals	SunTrust Banks	Initiated Coverage
11/24/2020	Kiniksa Pharmaceuticals	Evercore ISI	Initiated Coverage
6/30/2020	Kiniksa Pharmaceuticals	The Goldman Sachs Group	Boost Price Target
6/29/2020	Kiniksa Pharmaceuticals	Bank of America	Boost Price Target
6/29/2020	Kiniksa Pharmaceuticals	Wedbush	Boost Price Target
3/11/2020	Kiniksa Pharmaceuticals	JPMorgan Chase & Co.	Boost Price Target
3/11/2019	Kiniksa Pharmaceuticals	Barclays	Initiated Coverage
4/26/2021	Pliant Therapeutics	BTIG Research	Initiated Coverage
4/22/2021	Pliant Therapeutics	Piper Sandler	Boost Price Target
4/5/2021	Pliant Therapeutics	Citigroup	Initiated Coverage
4/5/2021	Pliant Therapeutics	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
8/12/2020	Pliant Therapeutics	Needham & Company LLC	Reiterated Rating
3/8/2021	Arcturus Therapeutics	B. Riley	Lower Price Target
3/2/2021	Arcturus Therapeutics	Roth Capital	Lower Price Target
1/7/2021	Arcturus Therapeutics	Wells Fargo & Company	Initiated Coverage
12/29/2020	Arcturus Therapeutics	Raymond James	Downgrade
12/14/2020	Arcturus Therapeutics	Smith Barney Citigroup	Boost Price Target
12/2/2020	Zogenix	Mizuho	Reiterated Rating
8/6/2020	Zogenix	Northland Securities	Reiterated Rating
6/26/2020	Zogenix	William Blair	Reiterated Rating
2/28/2020	Zogenix	LADENBURG THALM/SH SH	Reiterated Rating
2/14/2020	Zogenix	Stifel Nicolaus	Reiterated Rating
1/21/2020	Zogenix	Guggenheim	Reiterated Rating
12/6/2019	Zogenix	Piper Jaffray Companies	Reiterated Rating

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources